Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.

Autor: Salehi M; Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: mr-salehi@sina.tums.ac.ir., Alavi Darazam I; Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: ilad.alavi@sbmu.ac.ir., Nematollahi A; ReNAP Therapeutics, Tehran, Iran., Alimohammadi M; ReNAP Therapeutics, Tehran, Iran., Pouya S; ReNAP Therapeutics, Tehran, Iran., Alimohammadi R; ReNAP Therapeutics, Tehran, Iran., Khajavirad N; Department of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Porgoo M; ReNAP Therapeutics, Tehran, Iran., Sedghi M; ReNAP Therapeutics, Tehran, Iran., Mahdi Sepahi M; ReNAP Therapeutics, Tehran, Iran., Azimi M; Department of Medical Affairs, Pharmed Pajoohan Viera, Tehran, Iran., Hosseini H; Clinical Trial Center, Tehran University of Medical Sciences, Tehran, Iran., Mahmoud Hashemi S; Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Dehghanizadeh S; ReNAP Therapeutics, Tehran, Iran., Khoddami V; ReNAP Therapeutics, Tehran, Iran. Electronic address: v.khoddami@renap.ir.

Publikováno v: International immunopharmacology [Int Immunopharmacol] 2024 Jun 15; Vol. 134, pp. 112192. Date of Electronic Publication: 2024 May 17.